- LeMaitre Vascular Inc (LMAT, Financial) reported a 14% revenue increase, but missed analysts' expectations by 0.7%.
- Post-earnings, the stock plummeted 19.7%, despite optimistic EPS guidance, settling at a price of $84.77.
- Wall Street analysts offer an average price target suggesting 22.61% upside, while GuruFocus estimates indicate potential downside.
LeMaitre Vascular Inc (LMAT) recently announced a notable 14% boost in revenue, reaching $55.72 million. However, this achievement fell 0.7% short of Wall Street analysts' expectations. Despite issuing a robust end-of-year EPS guidance, the stock experienced a significant drop of 19.7% following the earnings announcement, with the current market price at $84.77. This reaction underscores market concerns and dissatisfaction.
Wall Street Analysts Forecast
Analyzing the one-year price targets provided by eight analysts, the average target for LeMaitre Vascular Inc (LMAT, Financial) stands at $105.63. This target encapsulates a spectrum, with a high forecast of $120.00 and a low of $90.00. The average projection suggests a potential upside of 22.61% from the current trading price of $86.15. Investors can access more comprehensive estimate data on the LeMaitre Vascular Inc (LMAT) Forecast page.
According to consensus from 11 brokerage firms, LeMaitre Vascular Inc (LMAT, Financial) holds an average brokerage recommendation of 2.4, categorized as "Outperform." This recommendation is based on a scale from 1 to 5, where 1 equates to a Strong Buy and 5 indicates a Sell.
GuruFocus's estimates suggest the GF Value for LeMaitre Vascular Inc (LMAT, Financial) one year from now is $76.83. This figure points to a potential downside of 10.82% compared to the current price of $86.15. The GF Value is derived by assessing historical trading multiples, past business growth, and projected future performance. Investors can explore additional detailed data on the LeMaitre Vascular Inc (LMAT) Summary page.
